PC-14Homo sapiens (Human)Cancer cell line
Also known as: PC14, PC 14
Quick Overview
Human lung adenocarcinoma cell line with EGFR mutations and potential for cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_1640 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Lymph node[UBERON:UBERON_0000029] |
Donor Information
Age | 45 |
---|---|
Age Category | Adult |
Sex | Male |
Race | asian |
Disease Information
Disease | Lung adenocarcinoma |
---|---|
Lineage | Lung |
Subtype | Lung Adenocarcinoma |
OncoTree Code | LUAD |
DepMap Information
Source Type | RIKEN |
---|---|
Source ID | ACH-000030_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | TP53 | p.Arg248Gln (c.743G>A) | Unspecified | Somatic mutation acquired during proliferation | PubMed=20575032 |
MutationSimple | EGFR | p.Glu746_Ala750del (c.2235_2249del15) | Unspecified | - | from parent cell line PC-9 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.
Shibata H., Ito T., Baba Y., Baba H.
Oncol. Lett. 8:1025-1030(2014).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Igishi T., Burioka N., Nanba E., Shimizu E.
Cancer Biol. Ther. 13:369-378(2012).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Cancer Res. 65:7276-7282(2005).
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Pathol. Res. Pract. 201:109-115(2005).
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hirohashi S., Inazawa J., Imoto I.
Hum. Mol. Genet. 14:997-1007(2005).
Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.
Fujisawa T.
Cancer Immunol. Immunother. 53:786-792(2004).
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.
Clin. Cancer Res. 9:4705-4713(2003).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Establishment of a drug sensitivity panel using human lung cancer cell lines.
Kohara H., Harada M.
Acta Med. Okayama 53:67-75(1999).
Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.
Hoshi A., Chen K.-M., Hamburger A.W.
Jpn. J. Clin. Oncol. 15:637-644(1985).